Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 218, Issue 2, Pages -Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20200887
Keywords
-
Categories
Funding
- National Institutes of Health [1R01AI138940]
- Milstein Program in Chemical Biology and Translational Medicine
- Potts Memorial Foundation
- William Randolph Hearst Foundation
Ask authors/readers for more resources
Research findings indicate that macrophage-derived type I interferons play a crucial role in the death of Mtb-infected macrophages in vitro, and blocking this signaling pathway may enhance the efficacy of TB drugs like rifampin. Further defining the pathway of type I interferon-mediated macrophage death may lead to more selective host-directed therapy for tuberculosis.
Macrophages help defend the host against Mycobacterium tuberculosis (Mtb), the major cause of tuberculosis (TB). Once phagocytized, Mtb resists killing by macrophages, replicates inside them, and leads to their death, releasing Mtb that can infect other cells. We found that the death of Mtb-infected mouse macrophages in vitro does not appear to proceed by a currently known pathway. Through genome-wide CRISPR-Cas9 screening, we identified a critical role for autocrine or paracrine signaling by macrophage-derived type I IFNs in the death of Mtb-infected macrophages in vitro, and blockade of type I IFN signaling augmented the effect of rifampin, a first-line TB drug, in Mtb-infected mice. Further definition of the pathway of type I IFN-mediated macrophage death may allow for host-directed therapy of TB that is more selective than systemic blockade of type I IFN signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available